SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
LXEO reported Third Quarter 2026 results. The price and volatility reaction is pending.
LXEOearnings

Earnings reactions, page 2

Lexeo Therapeutics, Inc. (LXEO) Q3 FY2026 earnings

November 16, 2026 · SharpeIQ Research Desk

Reported results

  • Research and Development expenses were $34.5 million for the three months ended September 30, 2026.
  • General and Administrative expenses were $5.9 million for the three months ended September 30, 2026.
  • Net loss was $38.3 million, or $0.43 per share (basic and diluted), for the three months ended September 30, 2026.
  • Participants in high-dose cohorts achieved an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) at latest assessment.
  • Participants in high-dose cohorts achieved a 44% mean reduction in premature ventricular contractions (PVC) burden at latest assessment.

Guidance

  • Lexeo expects to finalize pivotal study design, statistical analysis plan and confirmatory evidence strategy in 1H 2027.
  • Lexeo expects to initiate a pivotal study supporting accelerated approval in 2H 2027.
  • Cash, cash equivalents, and investments of $219.1 million are expected to provide operational runway into 2028.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →